{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T04:01:03Z","timestamp":1785038463586,"version":"3.55.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010446","name":"Institute for Basic Science","doi-asserted-by":"publisher","award":["IBS-R002-D1"],"award-info":[{"award-number":["IBS-R002-D1"]}],"id":[{"id":"10.13039\/501100010446","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Institute for Basic Science, Korea IBS-R002-D1"},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00260529"],"award-info":[{"award-number":["RS-2023-00260529"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-16063805"],"award-info":[{"award-number":["RS-2025-16063805"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF2022M3H9A2096186"],"award-info":[{"award-number":["NRF2022M3H9A2096186"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003716","name":"Korea Basic Science Institute","doi-asserted-by":"publisher","award":["A423200"],"award-info":[{"award-number":["A423200"]}],"id":[{"id":"10.13039\/501100003716","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-73881-9","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:39:54Z","timestamp":1780069194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glycine-modulating Slc6a20a-ASO restores NMDA receptor function in SHANK2 and SHANK3-mutant mice and cortical organoids"],"prefix":"10.1038","volume":"17","author":[{"given":"Junyeop Daniel","family":"Roh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusang","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2994-4510","authenticated-orcid":false,"given":"Yeji","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5956-9985","authenticated-orcid":false,"given":"Suho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo-Chang","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeonji","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjee","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Wook","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7210-5798","authenticated-orcid":false,"given":"Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0656-1269","authenticated-orcid":false,"given":"Jin Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5518-6584","authenticated-orcid":false,"given":"Eunjoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"73881_CR1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrn3504","volume":"14","author":"P Paoletti","year":"2013","unstructured":"Paoletti, P., Bellone, C. & Zhou, Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat. Rev. Neurosci. 14, 383\u2013400 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"73881_CR2","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1085\/jgp.201812032","volume":"150","author":"KB Hansen","year":"2018","unstructured":"Hansen, K. B. et al. Structure, function, and allosteric modulation of NMDA receptors. J. Gen. Physiol. 150, 1081\u20131105 (2018).","journal-title":"J. Gen. Physiol."},{"key":"73881_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41386-023-01614-3","volume":"49","author":"JE Hanson","year":"2024","unstructured":"Hanson, J. E. et al. Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry. Neuropsychopharmacology 49, 51\u201366 (2024).","journal-title":"Neuropsychopharmacology"},{"key":"73881_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/bs.apha.2016.01.006","volume":"76","author":"DT Balu","year":"2016","unstructured":"Balu, D. T. The NMDA receptor and schizophrenia: from pathophysiology to treatment. Adv. Pharm. 76, 351\u2013382 (2016).","journal-title":"Adv. Pharm."},{"key":"73881_CR5","doi-asserted-by":"crossref","unstructured":"Coyle, J. T., Basu, A., Benneyworth, M., Balu, D. & Konopaske, G. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Handb. Exp. Pharmacol. 267-295 (2012).","DOI":"10.1007\/978-3-642-25758-2_10"},{"key":"73881_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02253-w","volume":"12","author":"AO Kruse","year":"2022","unstructured":"Kruse, A. O. & Bustillo, J. R. Glutamatergic dysfunction in schizophrenia. Transl. Psychiatry 12, 500 (2022).","journal-title":"Transl. Psychiatry"},{"key":"73881_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.coph.2014.10.007","volume":"20C","author":"EJ Lee","year":"2015","unstructured":"Lee, E. J., Choi, S. Y. & Kim, E. NMDA receptor dysfunction in autism spectrum disorders. Curr. Opin. Pharm. 20C, 8\u201313 (2015).","journal-title":"Curr. Opin. Pharm."},{"key":"73881_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.coph.2020.12.006","volume":"56","author":"J Pagano","year":"2021","unstructured":"Pagano, J., Giona, F., Beretta, S., Verpelli, C. & Sala, C. N-methyl-d-aspartate receptor function in neuronal and synaptic development and signaling. Curr. Opin. Pharm. 56, 93\u2013101 (2021).","journal-title":"Curr. Opin. Pharm."},{"key":"73881_CR9","doi-asserted-by":"publisher","first-page":"15767","DOI":"10.1523\/JNEUROSCI.1175-13.2013","volume":"33","author":"LJ Duffney","year":"2013","unstructured":"Duffney, L. J. et al. Shank3 deficiency induces NMDA receptor hypofunction via an actin-dependent mechanism. J. Neurosci. 33, 15767\u201315778 (2013).","journal-title":"J. Neurosci."},{"key":"73881_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mcna.2022.05.002","volume":"107","author":"SI Deutsch","year":"2023","unstructured":"Deutsch, S. I. & Burket, J. A. From mouse to man: N-methyl-d-aspartic acid receptor activation as a promising pharmacotherapeutic strategy for autism spectrum disorders. Med. Clin. North Am. 107, 101\u2013117 (2023).","journal-title":"Med. Clin. North Am."},{"key":"73881_CR11","doi-asserted-by":"publisher","first-page":"102815","DOI":"10.1016\/j.conb.2023.102815","volume":"83","author":"L Mony","year":"2023","unstructured":"Mony, L. & Paoletti, P. Mechanisms of NMDA receptor regulation. Curr. Opin. Neurobiol. 83, 102815 (2023).","journal-title":"Curr. Opin. Neurobiol."},{"key":"73881_CR12","doi-asserted-by":"crossref","unstructured":"Deutsch, S. I., Luyo, Z. N. M. & Burket, J. A. Targeted NMDA receptor interventions for autism: developmentally determined expression of GluN2B and GluN2A-containing receptors and balanced allosteric modulatory approaches. Biomolecules 12 (2022).","DOI":"10.3390\/biom12020181"},{"key":"73881_CR13","doi-asserted-by":"crossref","unstructured":"Lee, K., Mills, Z., Cheung, P., Cheyne, J. E. & Montgomery, J. M. The role of zinc and NMDA receptors in autism spectrum disorders. Pharmaceuticals 16 (2022).","DOI":"10.3390\/ph16010001"},{"key":"73881_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.coph.2014.11.008","volume":"20C","author":"N Burnashev","year":"2015","unstructured":"Burnashev, N. & Szepetowski, P. NMDA receptor subunit mutations in neurodevelopmental disorders. Curr. Opin. Pharm. 20C, 73\u201382 (2015).","journal-title":"Curr. Opin. Pharm."},{"key":"73881_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejphar.2013.07.023","volume":"719","author":"C Verpelli","year":"2013","unstructured":"Verpelli, C., Montani, C., Vicidomini, C., Heise, C. & Sala, C. Mutations of the synapse genes and intellectual disability syndromes. Eur. J. Pharm. 719, 112\u2013116 (2013).","journal-title":"Eur. J. Pharm."},{"key":"73881_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/dneu.22093","volume":"74","author":"C Verpelli","year":"2014","unstructured":"Verpelli, C., Galimberti, I., Gomez-Mancilla, B. & Sala, C. Molecular basis for prospective pharmacological treatment strategies in intellectual disability syndromes. Dev. Neurobiol. 74, 197\u2013206 (2014).","journal-title":"Dev. Neurobiol."},{"key":"73881_CR17","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1474-4422(19)30244-3","volume":"18","author":"J Dalmau","year":"2019","unstructured":"Dalmau, J. et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 18, 1045\u20131057 (2019).","journal-title":"Lancet Neurol."},{"key":"73881_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/bs.apha.2017.08.005","volume":"82","author":"DR Lynch","year":"2018","unstructured":"Lynch, D. R. et al. Anti-NMDA receptor encephalitis: clinical features and basic mechanisms. Adv. Pharm. 82, 235\u2013260 (2018).","journal-title":"Adv. Pharm."},{"key":"73881_CR19","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1177\/0883073815600872","volume":"30","author":"H Harony-Nicolas","year":"2015","unstructured":"Harony-Nicolas, H., De Rubeis, S., Kolevzon, A. & Buxbaum, J. D. Phelan McDermid syndrome: from genetic discoveries to animal models and treatment. J. Child Neurol. 30, 1861\u20131870 (2015).","journal-title":"J. Child Neurol."},{"key":"73881_CR20","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1007\/s13311-015-0352-z","volume":"12","author":"JL Costales","year":"2015","unstructured":"Costales, J. L. & Kolevzon, A. Phelan-McDermid syndrome and SHANK3: implications for treatment. Neurotherapeutics 12, 620\u2013630 (2015).","journal-title":"Neurotherapeutics"},{"key":"73881_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1395867","volume":"15","author":"ML Dessus-Gilbert","year":"2024","unstructured":"Dessus-Gilbert, M. L. et al. NMDA antagonist agents for the treatment of symptoms in autism spectrum disorder: a systematic review and meta-analysis. Front. Pharm. 15, 1395867 (2024).","journal-title":"Front. Pharm."},{"key":"73881_CR22","doi-asserted-by":"publisher","first-page":"2875904","DOI":"10.1155\/2017\/2875904","volume":"2017","author":"L Yao","year":"2017","unstructured":"Yao, L. & Zhou, Q. Enhancing NMDA receptor function: recent progress on allosteric modulators. Neural Plast. 2017, 2875904 (2017).","journal-title":"Neural Plast."},{"key":"73881_CR23","doi-asserted-by":"publisher","first-page":"108631","DOI":"10.1016\/j.neuropharm.2021.108631","volume":"193","author":"D Stroebel","year":"2021","unstructured":"Stroebel, D., Mony, L. & Paoletti, P. Glycine agonism in ionotropic glutamate receptors. Neuropharmacology 193, 108631 (2021).","journal-title":"Neuropharmacology"},{"key":"73881_CR24","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.cell.2024.02.026","volume":"187","author":"Y Wei","year":"2024","unstructured":"Wei, Y. et al. Transport mechanism and pharmacology of the human GlyT1. Cell 187, 1719\u20131732.e1714 (2024).","journal-title":"Cell"},{"key":"73881_CR25","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/nrd3893","volume":"12","author":"RJ Harvey","year":"2013","unstructured":"Harvey, R. J. & Yee, B. K. Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat. Rev. Drug Discov. 12, 866\u2013885 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"73881_CR26","doi-asserted-by":"publisher","first-page":"109514","DOI":"10.1016\/j.neuropharm.2023.109514","volume":"232","author":"D Piniella","year":"2023","unstructured":"Piniella, D. & Zafra, F. Functional crosstalk of the glycine transporter GlyT1 and NMDA receptors. Neuropharmacology 232, 109514 (2023).","journal-title":"Neuropharmacology"},{"key":"73881_CR27","doi-asserted-by":"publisher","first-page":"266","DOI":"10.9740\/mhc.2016.11.266","volume":"6","author":"RW Schmidt","year":"2016","unstructured":"Schmidt, R. W. & Thompson, M. L. Glycinergic signaling in the human nervous system: An overview of therapeutic drug targets and clinical effects. Ment. Health Clin. 6, 266\u2013276 (2016).","journal-title":"Ment. Health Clin."},{"key":"73881_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.biopsych.2016.11.014","volume":"82","author":"D Bugarski-Kirola","year":"2017","unstructured":"Bugarski-Kirola, D. et al. Bitopertin in negative symptoms of schizophrenia-results from the phase III FlashLyte and DayLyte Studies. Biol. Psychiatry 82, 8\u201316 (2017).","journal-title":"Biol. Psychiatry"},{"key":"73881_CR29","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","volume":"71","author":"D Umbricht","year":"2014","unstructured":"Umbricht, D. et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry 71, 637\u2013646 (2014).","journal-title":"JAMA Psychiatry"},{"key":"73881_CR30","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00406-023-01576-z","volume":"273","author":"H Rosenbrock","year":"2023","unstructured":"Rosenbrock, H., Desch, M. & Wunderlich, G. Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 273, 1557\u20131566 (2023).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"73881_CR31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.neuropharm.2008.06.016","volume":"55","author":"KW Perry","year":"2008","unstructured":"Perry, K. W. et al. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Neuropharmacology 55, 743\u2013754 (2008).","journal-title":"Neuropharmacology"},{"key":"73881_CR32","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0896-6273(03)00672-X","volume":"40","author":"J Gomeza","year":"2003","unstructured":"Gomeza, J. et al. Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition. Neuron 40, 785\u2013796 (2003).","journal-title":"Neuron"},{"key":"73881_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.brainres.2006.08.089","volume":"1119","author":"K Szoke","year":"2006","unstructured":"Szoke, K. et al. Glycine transporter 1 expression in the ventral respiratory group is restricted to protoplasmic astrocytes. Brain Res. 1119, 182\u2013189 (2006).","journal-title":"Brain Res."},{"key":"73881_CR34","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012632","volume":"13","author":"M Bae","year":"2021","unstructured":"Bae, M. et al. SLC6A20 transporter: a novel regulator of brain glycine homeostasis and NMDAR function. EMBO Mol. Med 13, e12632 (2021).","journal-title":"EMBO Mol. Med"},{"key":"73881_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.857820","volume":"15","author":"J Kim","year":"2022","unstructured":"Kim, J. et al. Slc6a20a heterozygous and homozygous mutant mice display differential behavioral and transcriptomic changes. Front. Mol. Neurosci. 15, 857820 (2022).","journal-title":"Front. Mol. Neurosci."},{"key":"73881_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s11689-021-09397-8","volume":"13","author":"JP Delling","year":"2021","unstructured":"Delling, J. P. & Boeckers, T. M. Comparison of SHANK3 deficiency in animal models: phenotypes, treatment strategies, and translational implications. J. Neurodev. Disord. 13, 55 (2021).","journal-title":"J. Neurodev. Disord."},{"key":"73881_CR37","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.pnpbp.2017.11.019","volume":"84","author":"A Mossa","year":"2018","unstructured":"Mossa, A., Giona, F., Pagano, J., Sala, C. & Verpelli, C. SHANK genes in autism: Defining therapeutic targets. Prog. Neuropsychopharmacol. Biol. Psychiatry 84, 416\u2013423 (2018).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"73881_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02180-5","volume":"17","author":"K Phelan","year":"2022","unstructured":"Phelan, K. et al. Phelan-McDermid syndrome: a classification system after 30 years of experience. Orphanet J. Rare Dis. 17, 27 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"73881_CR39","doi-asserted-by":"publisher","first-page":"6482","DOI":"10.1038\/s41380-021-01140-y","volume":"26","author":"A Eltokhi","year":"2021","unstructured":"Eltokhi, A. et al. Imbalanced post- and extrasynaptic SHANK2A functions during development affect social behavior in SHANK2-mediated neuropsychiatric disorders. Mol. Psychiatry 26, 6482\u20136504 (2021).","journal-title":"Mol. Psychiatry"},{"key":"73881_CR40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nature11208","volume":"486","author":"H Won","year":"2012","unstructured":"Won, H. et al. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 486, 261\u2013265 (2012).","journal-title":"Nature"},{"key":"73881_CR41","doi-asserted-by":"publisher","first-page":"18448","DOI":"10.1523\/JNEUROSCI.3017-13.2013","volume":"33","author":"M Kouser","year":"2013","unstructured":"Kouser, M. et al. Loss of predominant Shank3 isoforms results in hippocampus-dependent impairments in behavior and synaptic transmission. J. Neurosci. 33, 18448\u201318468 (2013).","journal-title":"J. Neurosci."},{"key":"73881_CR42","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.neuron.2019.05.002","volume":"103","author":"F Koopmans","year":"2019","unstructured":"Koopmans, F. et al. SynGO: an evidence-based, expert-curated knowledge base for the synapse. Neuron 103, 217\u2013234.e214 (2019).","journal-title":"Neuron"},{"key":"73881_CR43","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.celrep.2015.04.064","volume":"11","author":"LJ Duffney","year":"2015","unstructured":"Duffney, L. J. et al. Autism-like deficits in Shank3-deficient mice are rescued by targeting actin regulators. Cell Rep. 11, 1400\u20131413 (2015).","journal-title":"Cell Rep."},{"key":"73881_CR44","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41593-018-0110-8","volume":"21","author":"L Qin","year":"2018","unstructured":"Qin, L. et al. Social deficits in Shank3-deficient mouse models of autism are rescued by histone deacetylase (HDAC) inhibition. Nat. Neurosci. 21, 564\u2013575 (2018).","journal-title":"Nat. Neurosci."},{"key":"73881_CR45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nature12618","volume":"503","author":"A Shcheglovitov","year":"2013","unstructured":"Shcheglovitov, A. et al. SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. Nature 503, 267\u2013271 (2013).","journal-title":"Nature"},{"key":"73881_CR46","doi-asserted-by":"crossref","unstructured":"Chiola, S. et al. Defective AMPA-mediated synaptic transmission and morphology in human neurons with hemizygous SHANK3 deletion engrafted in mouse prefrontal cortex. Mol. Psychiatry (2021).","DOI":"10.1038\/s41380-021-01023-2"},{"key":"73881_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33364-z","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Modeling human telencephalic development and autism-associated SHANK3 deficiency using organoids generated from single neural rosettes. Nat. Commun. 13, 5688 (2022).","journal-title":"Nat. Commun."},{"key":"73881_CR48","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2669","volume":"352","author":"F Yi","year":"2016","unstructured":"Yi, F. et al. Autism-associated SHANK3 haploinsufficiency causes Ih channelopathy in human neurons. Science 352, aaf2669 (2016).","journal-title":"Science"},{"key":"73881_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36993-x","volume":"9","author":"L Gouder","year":"2019","unstructured":"Gouder, L. et al. Altered spinogenesis in iPSC-derived cortical neurons from patients with autism carrying de novo SHANK3 mutations. Sci. Rep. 9, 94 (2019).","journal-title":"Sci. Rep."},{"key":"73881_CR50","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41593-019-0365-8","volume":"22","author":"K Zaslavsky","year":"2019","unstructured":"Zaslavsky, K. et al. SHANK2 mutations associated with autism spectrum disorder cause hyperconnectivity of human neurons. Nat. Neurosci. 22, 556\u2013564 (2019).","journal-title":"Nat. Neurosci."},{"key":"73881_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2021.773571","volume":"14","author":"AK Lutz","year":"2021","unstructured":"Lutz, A. K. et al. SHANK2 mutations result in dysregulation of the ERK1\/2 pathway in human induced pluripotent stem cells-derived neurons and Shank2(-\/-) mice. Front. Mol. Neurosci. 14, 773571 (2021).","journal-title":"Front. Mol. Neurosci."},{"key":"73881_CR52","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1038\/s41380-025-02947-9","volume":"30","author":"F Giona","year":"2025","unstructured":"Giona, F. et al. Shank3 modulates Rpl3 expression and protein synthesis via mGlu5: implications for Phelan McDermid syndrome. Mol. Psychiatry 30, 3599\u20133614 (2025).","journal-title":"Mol. Psychiatry"},{"key":"73881_CR53","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/mp.2016.30","volume":"22","author":"C Vicidomini","year":"2017","unstructured":"Vicidomini, C. et al. Pharmacological enhancement of mGlu5 receptors rescues behavioral deficits in SHANK3 knock-out mice. Mol. Psychiatry 22, 689\u2013702 (2017).","journal-title":"Mol. Psychiatry"},{"key":"73881_CR54","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/mp.2017.185","volume":"23","author":"A Kathuria","year":"2018","unstructured":"Kathuria, A. et al. Stem cell-derived neurons from autistic individuals with SHANK3 mutation show morphogenetic abnormalities during early development. Mol. Psychiatry 23, 735\u2013746 (2018).","journal-title":"Mol. Psychiatry"},{"key":"73881_CR55","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nature13975","volume":"518","author":"L Meng","year":"2015","unstructured":"Meng, L. et al. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature 518, 409\u2013412 (2015).","journal-title":"Nature"},{"key":"73881_CR56","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1242\/dev.026575","volume":"135","author":"MK Anas","year":"2008","unstructured":"Anas, M. K. et al. SIT1 is a betaine\/proline transporter that is activated in mouse eggs after fertilization and functions until the 2-cell stage. Development 135, 4123\u20134130 (2008).","journal-title":"Development"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73881-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73881-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73881-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T03:27:04Z","timestamp":1785036424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73881-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73881"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73881-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6987"}}